Numinus Wellness Co., Ltd. (TSE:NUMI) stock has returned the equivalent of 27% in the last month, quite a reversal of its recent strong performance. The decline ends a disastrous 12 months for shareholders, who have lost 51% in that time.
Although prices have fallen significantly, it’s understandable to feel complacent about Numinus Wellness’s median price-to-sales (or “P/S”) ratio of 1.5x for the Canadian pharmaceutical industry. Probably not. is also close to 1.2 times. However, without a rational basis for the P/S, investors may miss obvious opportunities or potential setbacks.
Check out our latest analysis for Numinus Wellness.
Numinus Wellness Achievements
Numinus Wellness’s revenue has been growing faster than most other companies, and it’s been in a good place recently. Perhaps many are expecting the strong earnings performance to wane, which may be holding back the P/S ratio from increasing. Even if this isn’t the case, existing shareholders are understandably optimistic about the future direction of the stock price.
If you want to know what analysts are predicting for the future, check out this article. free Report on Numinus Wellness.
Does the earnings forecast match the P/S ratio?
It’s only reassuring to see a P/S like Numinus Wellness’s when a company’s growth closely tracks its industry.
Looking back, the company’s sales grew an exceptional 106% last year. Also, in his most recent three-year period, his overall revenue has increased tremendously, helped by incredible short-term performance. So it’s safe to say that the company’s recent revenue growth has been impressive.
Looking ahead, the only analyst who follows the company says its revenue is expected to grow 40% annually over the next three years. This number is on track to significantly exceed his industry-wide annual growth forecast of 7.9%.
With this in mind, it’s interesting to see that Numinus Wellness’ P&L is roughly in line with its peers. It appears that some shareholders are skeptical about this outlook and are willing to accept a lower selling price.
Important points
Numinus Wellness’s stock price has fallen, and the company’s P/L is hovering around the industry median P/L. The power of the price-to-sales ratio is not primarily a valuation tool, but rather a gauge of current investor sentiment and future expectations.
Despite attractive revenue growth rates that outpace the industry, Numinus Wellness’s P&L isn’t as strong as we’d expect. Perhaps the uncertainty in the earnings forecast is keeping the P/S ratio in line with other companies in the industry. At least the risk of price declines appears to be contained, but investors seem to believe there could be some volatility in future returns.
Before you take the next step, you need to know the following: 4 warning signs for Numinus Wellness (1 is important!), we found it.
A company with a history of solid revenue growth will meet your needs.you might want to see this free A collection of other companies with high earnings growth and low P/E ratios.
Valuation is complex, but we help make it simple.
Check out our comprehensive analysis, including below, to see if Numinus Wellness is potentially overvalued or undervalued. Fair value estimates, risks and caveats, dividends, insider trading, and financial health.
See free analysis
Have feedback on this article? Curious about its content? contact Please contact us directly. Alternatively, email our editorial team at Simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.